摘要
Dear Editor,As a successful drug for inflammatory diseases,the application of TNF-αinhibitor on cancer therapy is limited by repeated administration and off-target effects.1 A body of evidence indicated that the anti-tumor efficacy of TNF-αinhibitor is unsatisfactory,though repeated administration was used to improve its efficacy in tumor-treating fields,it will also lead to severe side effects and high cost.2,3,4 Hence,an efficient and highly targeted TNF-αantibody delivery system is worth developing.
基金
supported in part by grants from the National Natural Sciences Foundation of China (82130106,32250016)
Nanjing Special Fund for Life and Health Science and Technology (202110016,China)
Changzhou Bureau of Science and Technology (CJ20210024,CZ20210010,CJ20220019,China)
Jiangsu TargetPharma Laboratories Inc.,China.
